PeterGLindeMD

Chronic Renal Failure & Dialysis, Kidney & Pancreas Transplantation

Physician

Dr. Linde is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Seghrenal Center 1001 Potero Ave
Bldg 100 3RD floor RM 342
San Francisco, CA 94110
Phone+1 415-206-2342

Brigham and Women's Hospital/Massachusetts General HospitalFellowship, Nephrology, 1998 - 2002
University of Pennsylvania Health SystemResidency, Internal Medicine, 1993 - 1996
Stanford University School of MedicineClass of 1993

PubMed

7 citations
Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
Nianhang Chen, Nastya Kassir, Abderrahmane Laadem, Ana Carolina Giuseppi, Jeevan K. Shetty
Journal of Clinical Pharmacology. 2021-01-01
7 citations
Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
Nianhang Chen, Nastya Kassir, Abderrahmane Laadem, Stephen E. Maxwell, Priya Sriraman
CPT. 2020-06-30
130 citations
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
M. Domenica Cappellini, Vip Viprakasit, Ali T Taher, Pencho Georgiev, Kevin H. Kuo
The New England Journal of Medicine. 2020-03-25

Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057September 23rd, 2020
Charles Bancroft Makes Quick Leap from Bristol Myers Exec Team to GSK; Medicxi Adds Two New Partners to Its TeamMarch 20th, 2020
Chutes & Ladders—Bristol Myers Squibb Appoints Mily to Strategy LeadMarch 20th, 2020